Rituximab in the treatment of anti-neutrophil cytoplasm antibody-associated vasculitis
{{output}}
The introduction of cyclophosphamide and high-dose glucocorticoids for anti-neutrophil cytoplasm antibody (ANCA)-associated vasculitis (AAV) has allowed a reduction in 1-year mortality from 80% to 10-20%. AAV is now a chronic disease, and greater emphasis has ... ...
